CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases

Clinical trial NCT07596680 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07596680
Sponsor: Nanjing Bioheng Biotech Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

SLE - Systemic Lupus Erythematosus Systemic Sclerosis ANCA Associated Vasculitis Idiopathic Inflammatory Myopathies Sjögren Syndrome

Start date: 2026-09-01
Primary completion: 2028-04-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.